Key result
Palliative pegylated liposomal doxorubicin is associated with high tolerability and clinical responses in cutaneous angiosarcoma.
Why the study?
Does pegylated liposomal doxorubicin provide a safe and effective palliative treatment for patients with cutaneous angiosarcoma?
Observational (n=8)
Yes
Does pegylated liposomal doxorubicin provide a safe and effective palliative treatment for patients with cutaneous angiosarcoma?
Pegylated liposomal doxorubicin combined with radiotherapy appears to be a useful and safe palliative alternative for cutaneous angiosarcoma when complete surgical resection is not possible.
BACKGROUND: Cutaneous angiosarcoma (AS) is a rare aggressive malignant vascular tumour of the skin. METHODS: We analysed the cases of cutaneous AS in two large dermatological departments of Saxony during the last 10 years. RESULTS: A total of eight AS cases were identified, mostly with head and neck involvement. Because of age and late diagnosis, only a minor part was completely resectable. As a palliative therapy pegylated liposomal doxorubicin was used. The drug was well tolerated. Our cases and those published in the literature suggest a high rate of responses and a possible sensitisation to subsequent radiation therapy. CONCLUSIONS: Although complete surgical resection followed by wide-field radiation therapy has been established as a therapeutic standard for AS, delay in diagnosis and older age with comorbidities warrant for a safe and effective adjuvant treatment. Pegylated liposomal doxorubicin combined with radiotherapy seems to be a useful and safe alternative.
No takes yet. Share an insight, caveat, or question.
Wollina et al. (2010) conducted an observational in Cutaneous angiosarcoma (n=8). Pegylated liposomal doxorubicin was evaluated. Pegylated liposomal doxorubicin was well tolerated as a palliative therapy in an observational series of 8 patients with cutaneous angiosarcoma, suggesting a high rate of clinical responses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: